The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: The effect of early versus delayed treatment

Cardiology in Review

Volumn 14, Issue 1, 2006, Pages 7-13

  Arnold, Renée J Goldberg ^a,b   Kim, Renée ^a,b   Tang, Boxiong ^c  

^a LONG ISLAND UNIVERSITY   (United States)

^b Pharmacon International Inc   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Argatroban; Delayed; Early; Heparin; Heparin induced thrombocytopenia; Incremental cost effectiveness; Temporal

Indexed keywords

ARGATROBAN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; HEPARIN; PIPECOLIC ACID DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; EARLY INTERVENTION; HEALTH CARE COST; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL CHARGE; HUMAN; MEDICAL LITERATURE; PHYSICIAN; PROBABILITY; RESOURCE MANAGEMENT; SENSITIVITY ANALYSIS; THERAPY DELAY; THROMBOSIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; THROMBOCYTOPENIA; TIME;

COST-BENEFIT ANALYSIS; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEPARIN; HUMANS; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; THROMBOCYTOPENIA; THROMBOSIS; TIME FACTORS;

EID: 33644873663     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000164011.17381.6f     Document Type: Article

References (28)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
2. Spinler SA, Dager W. Overview of heparin-induced thrombocytopenia. Am J Health Syst Pharm. 2003;60(suppl 5):S5-11.
3. Chong B. Heparin-induced thrombocytopenia. Aust NZ J Med. 1992;22:145-152.
4. Schmitt B, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993;305:208-215.
5. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
6. Hirsh J, Heddle N, Kelton J. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361-369.
7. Lewis B, Wallis D, Berkowitz S, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
8. Warkentin T, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):311S-337S.
9. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
10. Laster J, Cikrit D, Walker N, et al. The heparin-induced thrombocytopenia syndrome: an update. Surgery. 1987;102:763-770.
11. Cola C, Ansell J. Heparin-induced thrombocytopenia and arterial thrombosis: alternative therapies. Am Heart J. 1990;119(2 pt 1):368-374.
12. Warkentin T, Elavathil L, Hayward C, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
13. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost. 1995;73:21-28.
14. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
15. Chen J. Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications. Heart Dis. 2001;3:189-198.
16. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
17. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177-184.
18. Agency for Healthcare Research and Quality. HCUPnet, Healthcare Cost and Utilization Project, 2000 inpatient data.
19. Red Book. 107th ed. Montvale: Medical Economics Company, Inc; 2003.
20. Physician's Fee Reference. Milwaukee: Yale Wasserman DMD Medical Publishers, Ltd; 2003.
21. Warkentin T, Barkin R. Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy. 1999;19:181-195.
22. Harrington L, Hufnagel J. Heparin-induced thrombocytopenia and thrombosis syndrome. Heart Lung. 1990;86:153-158.
23. Deleted in proof.
24. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med. 2004;32:976-980.
25. Haas S. Heparin-induced thrombocytopenia (HIT) type II: a clinically heterogeneous hypercoagulable state requiring prompt intervention. Thromb Haemost. 2004;suppl S:42-45.
26. Wallis D, Workman D, Lewis B, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med Sci. 1999;106:629-635.
27. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961-966.
28. Gold M, Siegal J, Russell L, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.